With an eye on raising its profile among U.S. policymakers, Otsuka Pharmaceutical Co. Ltd., the maker of the antipsychotic drug Abilify, has entered the world of Washington, D.C., lobbying. The Japanese drugmaker has deployed Molly Ryan and Richard Thompson from its ranks to serve as its first lobbyists in the nation's capital, according to lobbying registration paperwork filed with Congress Monday. They registered to advocate for Otsuka under the auspices of its Rockville, Md.-based subsidiary, Otsuka America Pharmaceutical Inc. Ryan and Thompson plan to educate D.C. decision makers about the company, discuss ways to improve the delivery of mental health care in the U.S. and address the "[l]ack of innovative therapies for" chronic kidney disease, Otsuka's registration filing says. Affiliate publication Corporate Counsel has more.
Put the internet to work for you.
No comments:
Post a Comment